A Phase 2, Multicenter, Randomized Study to Compare the Efficacy and Safety of MK-7684A or MK-7684A Plus Docetaxel Versus Docetaxel Monotherapy in the Treatment of Participants With Metastatic Non-small Cell Lung Cancer With Progressive Disease After Treatment With a Platinum Doublet Chemotherapy and Immunotherapy

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-501252-28-00

Acronym

MK-7684A-002

Enrollment

150

Registered

2023-02-13

Start date

2021-04-15

Completion date

2024-10-10

Last updated

2024-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non Small Cell Lung cancer

Brief summary

Progression Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR) Assessment

Detailed description

Objective Response (OR) per RECIST 1.1 by BICR Assessment, Overall Survival (OS), Duration of Response (DOR) per RECIST 1.1 by BICR Assessment, Number of Participants Who Experienced an Adverse Event (AE), Number of Participants Who Discontinued Study Treatment Due to an AE

Interventions

DRUGMK-7684A

DRUGPlacebo to MK-7684A - normal saline

DRUGDOCETAXEL

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Progression Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR) Assessment	—

Secondary

Measure	Time frame
Objective Response (OR) per RECIST 1.1 by BICR Assessment, Overall Survival (OS), Duration of Response (DOR) per RECIST 1.1 by BICR Assessment, Number of Participants Who Experienced an Adverse Event (AE), Number of Participants Who Discontinued Study Treatment Due to an AE	—

Countries

Austria, Belgium, Denmark, Finland, France, Germany, Italy, Poland, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026